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ABSTRACT 
 
Thyroid carcinomas represent the most common endocrine cancers with their 
incidence increasing worldwide. Up to date there are no efficient treatments for 
patients affected by metastatic thyroid disease that is not responsive to 
radioiodine treatment. Sonic Hedgehog (Shh) pathway is active in regulating 
embryonic development of different organs as well as of the thyroid gland. The 
aberrant activation of Shh signaling has been found in several types of cancer 
and, according to recent evidences, it represents an important regulator of tumor-
stroma interaction. In this dissertation, we have studied expression, activation 
and molecular mechanisms regulating the Shh pathway in thyroid cancer and its 
involvement in the modulation of tumor stroma interaction in anaplastic thyroid 
cancer cells (ATC). Our results suggest that Shh signaling is activated through 
different mechanisms in thyroid cancer cells: in a non-canonical way in 
cooperation with other oncogenic pathways to promote and support thyroid 
neoplastic transformation as well as in a paracrine way in tumor-stroma 
interaction, supporting thyroid cancer cells invasion and migration. Our data 
therefore suggest that Shh signaling could be a novel therapeutic target in 
aggressive thyroid cancers. 
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1.0 BACKGROUND 	  
1.1 Thyroid gland 
 
 The thyroid is the largest endocrine gland, located on the anterior-inferior 
region of the neck. It consists of two conical lobes joined by a transverse 
segment, the isthmus. The gland is composed of functional units, the follicles, 
which are delimitated by an epithelial cuboidal cell layer and filled with colloid 
(the major constituent of the thyroid mass, representing a thyroglobulin protein 
reserve) (Williams textbook of Endocrinology 2003). The follicular cells, also 
called thyrocytes, are involved in iodine uptake and production of thyroid 
hormones. The parafollicular cells (C cells) represent the second thyroid cell 
population, blended among the follicular cells, producing the calcium-regulating 
hormone calcitonin (Kondo et al. 2006). The thyroid gland has an active role in 
the regulation of several biological functions through the synthesis and secretion 
of thyroid hormones, L-tri-iodothyronine (T3), the active hormone, and L-
thyroxine (T4) (De Lellis et al. 2004). The hypothalamic-pituitary axis finely 
regulates thyroid hormones production through Thyrotropin-Releasing-Hormone 
(TRH) produced by the hypothalamus and acting on the pituitary gland 
stimulating the synthesis of Thyroid-Stimulating-Hormone (TSH). The TSH 
hormone stimulates the follicular cells that undergo changes in their 
morphological features, from cuboidal to columnar, and secrete thyroid 
hormones (Kondo et al. 2006; Williams textbook of Endocrinology 2003). 
 
1.2 Thyroid carcinoma 
 
  Thyroid carcinoma, the most common endocrine cancer, is classified on 
the basis of its cellular origins, histological appearance and prognosis (De Lellis 
et al. 2004). Follicular thyroid cell-derived tumors account for the majority of 
thyroid cancers and include well-differentiated carcinoma (WDTC), which 
retains many features of thyroid differentiation, poorly differentiated carcinoma 
(PDTC) and anaplastic carcinoma (ATC) that is completely undifferentiated 
highly aggressive and therapy resistant (Cooper et al. 2009). Well-differentiated 
carcinoma is further classified in papillary thyroid carcinoma (PTC) and 
follicular thyroid carcinoma (FTC). PTC represents 80% of all thyroid cancers 
whereas FTC represents only a small fraction of thyroid cancers (~15%) (The 
Cancer Genome Atlas Research Network 2014, Schlumberger and Caillou 
2000). However, PTC and FTC may de-differentiate and lead to more aggressive 
thyroid cancers (The Cancer Genome Atlas Research Network 2014, Bhaijee 
and Nikiforov 2011). Parafollicular C cell-derived medullary thyroid cancer 
(MTC) accounts for only 2-5% of thyroid cancers (Wells et al. 2015).  
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1.2.1 Follicular cell derived thyroid carcinoma  
 
 Papillary thyroid carcinoma (PTC) is characterized by papillary 
structures, which replace the normal thyroid follicular structures, and by typical 
nuclear features, such as a hypodense chromatine (ground-glass nuclei)  (Vu-
Phan and Koenig 2014). Several histological PTC subtypes exist, such as the 
follicular variant (FV), characterized by a follicular growth pattern (The Cancer 
Genome Atlas Research Network 2014) and the tall cell variant (TCV) 
consisting of cells that have a height that is three times than their width (Al-
Brahim and Asa 2006; Lloyd et al. 2011; LiVolsi 2010).  The mitogen-activated 
protein kinase (MAPK) signaling pathway has an important role in the 
regulation of thyroid cell proliferation, survival and tumorigenesis. Different 
genetic alterations of genes encoding mediators of the MAPK signaling pathway 
have been identified in PTC. BRAF is a serine-threonine kinase member of the 
RAF family proteins, involved in the MAPK signaling cascade (Nikiforov and 
Nikiforova 2011; Vu-Phan and Koenig 2014). The BRAFV600E mutation is the 
most frequent genetic alteration in the classic papillary variant of PTC (~45%) 
and it is also found in tall cell variant PTC, while it is rare in the follicular 
variant PTC (Xing 2005; Adeniran et al. 2006). The BRAFV600E point 
mutation involves a thymine to adenine substitution in the nucleotide position 
1799, which leads to a valine to glutamate substitution in the 600 amino acid 
residue (Ciampi and Nikiforov 2005; Xing 2005). This mutation causes the 
BRAF constitutive activation and hence the MAPK pathway prolonged 
stimulation (Cantwell-Dorris et al. 2011; Wan et al. 2004). The AKAP9/BRAF 
rearrangement, present only in a small fraction of PTCs (1-2%), is due to a 
paracentric inversion of chromosome 7q leading to the fusion between the 
BRAF protein kinase domain and the A-kinase anchor protein 9 (AKAP9) gene 
(Ciampi et al. 2005). RET is a cell surface receptor tyrosine kinase, normally 
expressed in the developing central and peripheral nervous system (Schuchardt 
et al. 1994), and its gene is located on chromosome 10q11.2. In thyroid, RET is 
normally expressed in para-follicular but not in follicular thyroid cells (Bhaijee 
and Nikiforov 2011; Kondo et al. 2006). Alterations of this gene have been 
found in ~15% of PTC (Vu-Phan and Koenig 2014) and are characterized by 
chromosomal rearrangements where the 3’- terminal sequence of RET, encoding 
the tyrosine kinase domain, is fused in frame to 5’- terminal sequence of 
heterologous genes, forming the chimeric RET/PTC oncogenes. Several 
RET/PTC variants have been described in PTC, differing for the RET-gene 
fusion partners. RET/PTC1 and RET/PTC3 are the most frequent RET 
rearrangements in PTC (Santoro et al. 1994); in RET/PTC1, RET tyrosine kinase 
domain is fused with the coiled-coil domain-containing gene 6 (CCDC6, also 
known as H4), in RET/PTC3, instead, the tyrosine kinase domain of RET is 
fused with the nuclear receptor co-activator 4 (NCOA4, also known as ELE1) 
(Ciampi and Nikiforov 2005; Santoro et al. 2006). The RET partners share some 
common features: a) they are expressed in thyroid follicular cells and provide an 
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active promoter for the expression of rearranged RET tyrosine kinase domain; b) 
they contain protein-protein dimerization motifs and mediate ligand-independent 
dimerization and activation of the truncated RET protein (Tong et al. 1997), 
leading to the activation of several intracellular signalings, such as the MAPK 
and PI3K-AKT pathways through signaling adaptors recruitment to the 
phosphorylated Tyr1062 which is localized on the intracellular domain of the 
RET/PTC protein (Miyagi et al. 2004; Hayashi et al. 2000). The intracellular G-
protein RAS regulates important cellular processes such as growth, 
differentiation and survival. RAS is a small GTP-ase involved in the signal 
transduction from cell membrane receptor tyrosine kinases and G-protein 
coupled receptors through the MAPK and PI3K-AKT pathway activation 
(Nikiforov and Nikiforova 2011). Three RAS genes encode four homologous G-
proteins, HRAS, located on chromosome 11p11, KRAS4A ad KRAS4B 
(resulting from an alternative splicing), located on chromosome 12p12 and 
NRAS located on chromosome 1p13 (Downward J 2003). Gain-of-function 
point mutations of HRAS and NRAS have been found in about 15% of PTCs, in 
particular in the follicular variant PTC (Adeniran et al. 2006; Zhu et al. 2003). 
 	   Follicular thyroid cancer (FTC) is the second most common well-
differentiated thyroid carcinoma. FTC is characterized by thyroid follicular 
organization in the absence of papillary structures and typical nuclear features. 
The similar histological features make the differential diagnosis between 
follicular adenoma and FTC sometimes difficult (Grebe and Hay 1995; Vu-Phan 
and Koenig 2014). Nonetheless, genetically PTCs and FTCs are quite different. 
An important oncogenic alteration found in FTC is the PAX8-PPARγ 
chromosomal rearrangement. Paired box 8 (PAX8) gene, located on 
chromosome 2, encodes a transcription factor involved in thyroid development 
driving the expression of many thyroid-specific genes. The peroxisome 
proliferator-activated receptor γ (PPARγ) gene is located on chromosome 3 and 
encodes a member of steroidal hormones-binding nuclear receptor transcription 
factor family able to form heterodimers with the retinoid X receptor (RXR). It is 
an important regulator of adipogenesis and usually, it is expressed at low levels 
in thyroid (Vu-Phan and Koenig 2014). The PAX8-PPARγ rearrangement 
results from t(2;3)(q13;p25) chromosomal translocation which leads to the 
fusion of the promoter and most of the PAX8 gene to the coding exons of the 
PPARγ gene (Kroll et al. 2000). The resulting fusion protein is composed by the 
PAX8 DNA binding domain and PPARγ receptor and has been shown to be a 
dominant negative inhibitor of wildtype PPARγ transcriptional activity (Kroll et 
al. 2000; Yin et al. 2009). PPARγ has often been found down-regulated in 
different types of thyroid cancers suggesting a tumor suppressive function. 
Therefore the fusion protein may support the thyroid tumorigenesis also through 
repressing the PPARγ target genes transcription (Vu-Phan and Koenig 2014). 
This rearrangement has been found in ~35% of FTC and, at a smaller fraction, in 
follicular variant PTC as well as in follicular adenoma (Eberhardt et al. 2010). 
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Finally, constitutively activating RAS mutations, in codon 61 of NRAS and 
HRAS genes in particular, are present in ~ 40% of FTCs (Nikiforov 2011). 
 
 Poorly differentiated thyroid carcinoma (PDTC) is a follicular cell 
derived carcinoma that represents a morphological intermediate between well-
differentiated thyroid carcinoma and undifferentiated (anaplastic) thyroid 
carcinoma and accounts for 10% of all thyroid cancers (Volante et al. 2010; 
DeLellis et al. 2004). Activating point mutations of the NRAS gene (codon 61) 
are the most frequent genetic alteration found in PDTC (Volante et al. 2009). 
The BRAFV600E point mutation occurs in 5-20% of PDTC and is mainly found 
in PDTC that derives from PTC rather than PDTC arising from FTC (Nikiforova 
et al. 2003; Soares et al. 2011). TP53 is a nuclear transcription factor involved in 
cell cycle and apoptosis regulation. TP53 mutations, in the majority of cases on 
exons 5-9, occur in 40-50% of PDTC and seem to be an important step to 
promote progression and dedifferentiation of thyroid tumors (Soares et al. 2011). 
Mutations of PI3K-AKT pathway effectors have also been found in PDTC, in 
particular activation of oncogenes such as PIK3CA (5-14%) and AKT1 (5-10%) 
or inactivation of tumor suppressor genes such as PTEN (20%) (Nikiforov and 
Nikiforova 2011).  
 
 Anaplastic thyroid carcinoma (ATC) is the most aggressive form of 
thyroid cancer. ATC may result as the last step of the gradual thyroid cancer 
progression from a well-differentiated to an undifferentiated carcinoma or it can 
arise de novo. ATC accounts for 1-2% of all thyroid tumors. TP53 loss of 
function mutations are common genetic events involved in the tumor 
progression and occur at high rate (50-80%of cases) in ATC (Ricarte-Filho et al. 
2009). Activating point mutations of RAS gene occur in 40 to 60% of cases (Pita 
et al. 2014) while the BRAFV600E point mutation has been found in up to 40% 
of cases (Ricarte-Filho et al. 2009). Both mutations are important events 
involved in the dedifferentiation process, although additional genetic alterations 
are required to promote tumor progression (Nikiforov YE 2004). Mutations of 
genes involved in the PI3K-AKT pathway, in particular mutations of PI3KCA 
gene (5-25%), PTEN (5-15%) and AKT1 (5-10%), have been identified in ATC 
(Rosai et al. 2015; Garcia-Rostan et al. 2005). Amplification of PIK3CA locus in 
3q26.3 has been found in 40% of ATC (Ragazzi et al. 2014). Other frequent and 
important genetic alterations found in ATC are represented by TERT (human 
telomerase reverse transcriptase) promoter activating mutations. In particular, 
two mutations located at -124 and -146  bp upstream from the ATG start site 
(−124 G>A and −146 G>A) have been detected in up to 50% of ATCs 
(frequently occurring together with BRAFV600E point mutation) (Horn et al. 
2013; Rosai et al. 2015). Finally, an important involvement of miRNAs in 
thyroid tumorigenesis has been shown. Some miRNAs, in particular miR-200 
and miR-30 family, have been found down-regulated in ATC, suggesting a 
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critical role in the acquisition of aggressive tumor features (Fuziwara and 
Kimura 2014; Visone et al. 2007). 
 
1.2.2 Parafollicular cell-derived thyroid carcinoma 
 
 Medullary thyroid cancer (MTC) arises from parafollicular thyroid cells 
and accounts for 5% of all thyroid cancers (Wells et al. 2013). MTCs occur in 
hereditary form (25%) as the main component of the hereditary Multiple 
Endocrine Neoplasia type 2 (MEN2) syndromes, together with 
pheochromocytoma, while in 75% of cases they occur in sporadic form. Both 
hereditary and sporadic MTCs are characterized by RET activating point 
mutations. MEN2 syndrome is classified in MEN2A (85%) and MEN2B (15%) 
(Wells et al. 2013; Hedayati et al. 2016). In MEN2A RET germline mutations in 
codons 609, 611, 618, or 620 of exon 10 or codon 634 of exon 11 occur in a high 
number of cases (Raue and Frank-raue 2012). In MEN2B, RET germline 
mutations occur in exon 16 (M918T) in ~95% of cases and, only in the 5%, in 
exon 15 (A883F) (Smith et al. 1997). RET mutations are present in ~50% of 
sporadic MTC (Marsh et al.1996). Somatic mutations of HRAS, KRAS and 
rarely NRAS have been found in 18-80% of RET negative sporadic MTCs 
(Ciampi et al. 2013).	  	  
 
1.3 Role of stroma in thyroid cancer 
 
A growing body of evidences indicates the stroma as a key player in 
tumorigenesis to support the growth, maintenance and progression of cancer. 
The constant bidirectional interaction between epithelial cancer cells and stromal 
components coordinate tumor cell growth, migration, invasion, metastasis and 
drug resistance (Mueller et al 2004). Cellular microenvironment is composed of 
several cell types such as cancer associated fibroblasts (CAFs), endothelial cells, 
immune cells, adipocytes and stem cells interacting in a dynamic manner with 
extracellular matrix (ECM) in the regulation of tumorigenesis. Stroma 
composition changes among the different histotypes of thyroid cancers; in PTC 
it is mainly characterized by immune/inflammatory cells, while in ATC and 
MTC as well as in metastatic PTC it has been described a desmoplastic stromal 
reaction, correlating to aggressiveness and lymph node metastasis (Koperek et 
al. 2007; Koperek et al. 2013). More in detail, the production of collagen type I 
mediated by stromal fibroblasts seems to be regulated by thyroid cancer cells 
which induce procollagen type I mRNA translation in neighboring stromal cells 
in a paracrine fashion (Dahlman et al. 2002). Anaplastic thyroid cancer cells are 
able to stimulate stromal cells producing growth factors and cytokine such as 
Platelet-derived growth factor (PDGF), involved in the stromal response 
(Forsberg et al. 1993), together with induction of transforming growth factor-β 
(TGF-β) which has been demonstrated to be involved in the desmoplastic 
reaction in scirrhous gastric cancer (Mahara et al. 1994). Activated stromal 
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fibroblasts are characterized by three molecular markers namely, Fibroblast 
activation protein α, (FAPα), Tenascin-C (Tn-C) and α-smooth muscle actin (α-
SMA). In the MTC stromal compartment all three fibroblast activation markers 
are highly expressed compared to stromal compartment of normal thyroid gland 
with a significant correlation between degree of desmoplasia and expression of 
activation markers (Koperek et al. 2007). Moreover, up-regulation of FAPα and 
Tn-C has been found in metastasizing PTCs compared to non-metastasizing 
PTCs. Desmoplastic stromal reaction seems to be significantly associated to 
invasive behavior of papillary thyroid microcarcinomas and, in combination 
with calcification, it is associated to lymph node metastasis (Koperek et al. 2011; 
Koperek et al. 2013). 
 
1.4 Sonic Hedgehog signaling pathway 
 
 The Sonic Hedgehog pathway plays an important role in regulating cell 
growth, differentiation and tissue patterning during normal human embryonic 
development. It can act as morphogen in developing tissues in a dose-dependent 
manner through the induction of different effects on various cell types and it 
may act as a mitogen that regulates cell proliferation of developing organs 
(Ingham and McMahon 2001). In adults this pathway is mainly quiescent but has 
important functions in the regulation of tissue homeostasis, continuous renewal 
and repair of adult tissues and stem cell maintenance (Hooper and Scott 2005). 
The Shh signaling pathway has also been recognized to be one of the most 
important signaling pathways involved in several types of human cancer where it 
promotes growth, enables proliferation of tumor stem cells and regulates tumor-
stroma interaction (Heretsch et al. 2010). 
 
 Shh signaling pathway activation is typically initiated in the target cell by 
binding secreted hedgehog ligands to the protein receptor Patched (Ptch), a 12-
span-transmembrane protein (Fig.1). In mammals the Hh-genes encode three 
ligands i) Sonic Hedgehog (Shh), the most extensively characterized, ii) Indian 
Hedgehog (Ihh) iii) Desert Hedgehog (Dhh), which are characterized by 
different spatial and temporal distribution patterns (Ingham and McMahon 
2001). In vertebrates the Shh pathway localizes at the primary cilium, a slim 
microtubule-based organelle that protrudes from the cellular surface. In 
particular, Ptch receptor as well as the seven-span-transmembrane receptor 
Smoothned (Smo) show dynamic trafficking in cilia depending on Shh ligand 
binding (Goetz and Anderson 2010; Rohatgi et al. 2007). In the absence of Shh 
ligand, the Ptch receptor is localized to the base of the cilia and inhibits Smo 
(located on the membrane of the intracellular endosomes) by preventing its 
localization to the cell surface (Gupta et al. 2010); upon Shh binding, Ptch looses 
its inhibitory activity on Smo, which, in turn, moves into the cilium and 
transduces the Shh signaling downstream. Finally, Ptch receptor is internalized 
and degraded. On the cell surface there are further regulators that increase or 
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reduce Shh ligands binding to Ptch receptor. Hhip protein is a negative regulator 
that competes with Ptch for Shh ligand binding; on the contrary, positive 
regulators like immunoglobulin (Ig)/fibronectin (Fn)-repeat-containing proteins 
Boc and Cdo, together with glycosidyl-phosphatidylinositol (GPI)-anchored 
membrane-bound protein Gas1 favour binding of Shh ligands to Ptch (Heretsch 
et al. 2010). Shh ligands binding to Ptch receptor triggers a cascade of 
downstream events that culminates in the activation of the zinc finger 
transcription factors glioma-associated oncogene Gli. There are three different 
Gli proteins in mammals, Gli1 that acts as a constitutive activator, Gli2 and Gli3 
both containing an activator and repressor domains. Gli proteins are 
characterized by five highly conserved tandem zinc fingers, conserved N-
terminal domain, several PKA phosphorylation sites, and additional small 
conserved regions in the C-terminal domain. Activated Gli proteins (GliA) 
translocate into the nucleus where they mediate the transcription of different 
target genes such as D-type cyclins, B-cell lymphoma 2 (Bcl2), vascular 
endothelial growth factor (VEGF), myelocytomatosis oncogene (Myc), snail 
family zinc finger (Snail) and Nanog homeobox (Nanog) (Scales and de Sauvage 
2009). Gli transcription factors also mediate Gli1 and Ptch transcription, the last 
one functioning as a negative feedback in the Shh pathway regulation. In the 
absence of Shh ligand Gli transcription factors are sequestered in the cytoplasm 
by a negative regulator protein, Suppressor of fused (SuFu), that targets Gli for 
phosphorylation mediated by protein kinase A (PKA), glycogen synthase kinase 
3 (GSK3β) and casein kinase 1 (CK1ε). Phosphorylated Gli proteins, bound to 
the adapter protein βTrCP, are subjected to ubiquitination mediated by Cul1-
based E3 ligases and are completely degraded (in the case of Gli1 and Gli2) or 
partially degraded (in the case of Gli3), generating repressive forms (Gli3R) 
(Wen et al. 2010; Pan et al. 2006). 
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Figure 1. Schematic representation of Hedgehog signaling. Shh pathway cascade is triggered 
in receiving cell by Shh ligand binding to Ptch1 receptor. In the absence of Shh ligand (Off-
State), Ptch1 inhibits Smo receptor localization to the cell surface. Full length Gli proteins are 
phosphorylated and ubiquitinated to be proteolytically processed and generate the repressor Gli 
R (mainly derived from Gli3) that prevent Shh target genes transcription. In the presence of Shh 
ligand binding, Ptch1 receptor is internalized and degraded. Shh ligand binding can be repressed 
by Hhip and supported by Boc/Cdo and Gas1. Active Smo receptor promotes generation of GliA 
(mainly derived from Gli1 and Gli2) that is able to translocate to the nucleus where it activates 
Shh target genes transcription. 
 
1.4.1 Mechanisms of Sonic Hedgehog pathway activation in cancer 
 
 Shh pathway alteration has been seen in several types of human cancer 
and three models of activation have recently been described (Fig.2). 
 
Type I Sonic Hedgehog signaling: ligand independent (mutation driven). 
 
 Type I ligand-independent model of activation is characterized by loss-
of-function mutations in the negative regulators Ptch or SuFu, or gain-of-
function mutations in Smo receptor (Fig.2A). These events lead to the 
constitutive activation of Shh pathway in a cell-autonomous manner in the 
absence of the ligand, and this activation is alone sufficient for tumor initiation 
and maintenance of different cancers (Scales and Sauvage 2009). For example, 
in Gorlin’s syndrome (or basal cell nevus syndrome) inherited inactivating 
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mutations in the Ptch1 gene on chromosome 9 are responsible for ligand-
independent activation of the Shh pathway that predisposes the patients to high 
incidence of basal cell carcinoma (BCC), medulloblastoma, and 
rhabdomyosarcoma (Scales and Sauvage 2009). Ligand-independent activation 
of Shh pathway is also observed in almost all cases of sporadic BCC, either 
through tumor-suppressor gene Ptch1 inactivating mutations and/or loss of 
heterozygosity (>85%) or through activating mutation in Smo receptor (~10%), 
generating SmoM2 protein (Trp535Leu) (Reifenberger et al. 2005). Finally, 
inappropriate Shh pathway activation is observed in about one third of all 
medulloblastomas due to sporadic mutations in either Ptch1 or SuFu or Gli1 up-
regulation (>30%) and in sporadic rhabdomyosarcomas where it has been 
described the loss of heterozygosity of the two negative regulators Ptch1 and 
Sufu (Tostar et al. 2006; Taylor et al. 2002). 
 
Type II Sonic Hedgehog signaling: ligand dependent (autocrine mechanism). 
 
 Ligand dependent activation has been described in many tumors such as 
lung, breast, pancreatic, gastric, prostate, melanoma and colorectal cancers. 
These tumors are able to produce and respond to Shh ligand through both auto- 
or juxtacrine mechanisms where Shh ligand is produced and acts on the same 
tumor cells (or neighboring tumor cells) to stimulate proliferation and/or 
survival leading to tumor growth (Fig.2B) (Scales and Sauvage 2009). 
  
Type III Sonic Hedgehog signaling: ligand dependent (paracrine mechanism). 
 
  In diffrent cancer models the tumor cells have been described to 
overproduce the Shh ligand that can stimulate stroma cells near the tumor in a 
paracrine manner. Shh ligand secreted by cancer cells acts on stroma cells 
leading to Shh pathway activation in the tumor microenvironment (Fig.2C). 
Upon Shh target genes transcription, the mesenchymal cells produce growth and 
survival signals that are feeded back to the tumor cells such as Insulin-like 
growth factor (IGF), Wnt and VEGF enhancing cancer progression and 
aggressiveness (Gupta et al. 2010). Tumor growth is then indirectly supported by 
mechanisms originated in the stroma cells (Heretsch et al. 2010). Therefore, 
paracrine ligand dependent Shh signaling activation has been described to 
mediate tumor maintenance and growth more than tumor initiation. A variant of 
this Shh signaling is the “reverse paracrine signaling” (Fig.2D) where the Shh 
ligand is secreted from the stroma and is received by the tumor cells. The reverse 
paracrine signaling is typical of hematological malignancies such as leukemia or 
multiple myeloma and B-cell lymphoma where stromal Shh is able to supply the 
appropriate microenvironment for tumor growth (Scales and de Sauvage 2009) 
and at the same time Shh ligand secreted from bone marrow stroma up-regulates 
anti-apoptotic factors, such as Bcl2, supporting cancerous B cells survival 
(Hegde et al. 2008).  
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Figure 2. Mechanisms of Hedgehog signaling activation in cancer. A) Shh pathway is 
constitutively active, even in the absence of Shh ligands, due to inactivating mutations in Ptch1 
receptor or in the negative regulator Sufu or due to activating mutations in Smo receptor. B) 
Cancer cells both produce and respond to Shh ligand leading to cell-autonomous signaling 
activation. C) Cancer cells produce and secrete Shh ligand which is received by stromal cells that 
then activate the pathway. In turn, stromal cells produce other growth or survival signals to the 
cancer cells. D) Stromal cells secrete Shh ligand that leads to Shh pathway activation in cancer 
cells. (Modified from Heretsch et al. 2010)  
 
 Several evidences describe the Hedgehog pathway as an important 
regulator of cancer-stroma interaction (Olive et al. 2009). Shh ligand, produced 
from pancreatic cancer cells and acting on pancreatic stromal cells, is able to 
activate the Hedgehog pathway in pancreatic stroma promoting the transcription 
of downstream genes. Shh signaling has been demonstrated to be involved in the 
regulation of the pancreatic tumor microenvironment, tumor development 
promotion and metastasis (Li et al. 2014). It has also been demonstrated an 
important role of Shh signaling in the stromal response to Shh ligand in the 
pancreatic ductal adenocarcinoma (PDA) formation. Lee and coworker (2014) 
have recently shown that Shh signaling inhibition in PDA mouse models 
accelerates progression of oncogenic Kras-driven disease, while pharmacologic 
inhibition of Shh pathway induced an alteration in the balance between stromal 
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and epithelial elements reducing desmoplastic reaction and promoting tumor 
growth. Shh signaling has been shown to be also involved in human tissues 
injury and inflammation where Shh ligand, secreted from injured or damaged 
cells, acts on stromal microenvironment (fibroblasts, immune cells and resident 
quiescent cells) to activate Shh signaling pathway. 
 
 Cancer stem cells (CSC) have the ability to both generate additional stem 
cells (self-renewal) and differentiate (multipotency), supporting tumor growth 
and propagation. Shh signaling pathway is involved in the CSC self-renewal 
regulation in different models of cancer such as breast, glioma and multiple 
myeloma (Theunissen and de Sauvage 2009). The Shh ligand can be produced 
either by CSCs or by the surrounding stroma and activates Shh signaling in self-
renewing CSCs (Fig.3). Moreover, Shh signaling activation leads to CSC 
differentiation into cancer cells forming the bulk of the tumor (Gupta et al. 
2010). Conventional chemotherapy and radiation are typically ineffective to 
fight CSCs that have been hypothesized as the cause of cancer relapse after 
treatment with conventional therapies. Shh signaling pathway activation in 
several types of CSCs allows to consider Shh inhibition as a promising 
therapeutic target to fight CSCs (Scales and de Sauvage 2009). 
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Figure 3. Hedgehog pathway in cancer stem cells. Cancer stem cells produce their own Shh 
ligand, or receive it from stromal cells, activating Shh signaling that stimulates and supports stem 
cell self-renewing. As well as CSC differentiation into cancer cells that form the bulk of tumor. 
(Modified from Gupta et al. 2010). 
 
1.5 Hedgehog pathway inhibitors (HPIs) 
 
 The great involvement of aberrant Shh signaling pathway in several 
cancers makes it an attractive anticancer drug target. Several small molecular 
inhibitors, either natural products or synthetic compounds, have been developed 
in order to target different regulative elements of Shh pathway. 
 
1.5.1 Smoothened inhibitors 	  
 The steroidal alkaloid cyclopamine was isolated from the Veratrum 
californicum and identified as a teratogen compound responsible for severe 
craniofacial defects such as cyclopia and brain malformations (Keeler and Binns 
1968). It was afterwards proven that cyclopamine teratogenic effects resulted 
from its ability to inhibit Shh pathway. Cyclopamine binds directly to Smo 
protein on the heptahelical domain that represents its specific binding site. 
Cyclopamine binding influences the Smo protein conformation leading to the 
inhibition of Smo activity, even in the presence of Shh ligand (Chen et al. 2002). 
Therefore this drug represents a valuable strategy for the treatment of tumors 
characterized by Smo hyperactivation due to Ptch loss of function mutations or 
Smo gain of function mutations and has been provided for the treatment of Basal 
cell carcinoma (BCC) through the use of a cream formulation applied locally. 
BCCs treated with cyclopamine have shown a substantial regression (Tabs and 
Avci 2004). However, cyclopamine displays low affinity for the Smo receptor, 
poor oral bioavailability, low metabolic stability, and suboptimal 
pharmacokinetics therefore, its pharmacological and physicochemical properties 
do not make it an ideal drug (Tremblay et al. 2008). For this reason, more potent 
derivatives of cyclopamine have been synthesized. One of the first semi-
synthetic cyclopamine-based inhibitors is KAAD-cyclopamine (3-keto-N-
(aminocaproyl-dihydrocinnamoyl cyclopamine) showing higher potency and 
reduced cytotoxicity compared to its precursor (Heretsch et al. 2010). The small 
molecule Hedgehog inhibitor IPI-269609 (Infinity Pharmaceuticals), another 
cyclopamine derivative, retains the potency of cyclopamine but shows high 
solubility and acid stability. It resembles the properties of cyclopamine to block 
Hedgehog pathway in particular in pancreatic cancer cells in vitro, impairing cell 
motility and colony formation, and inhibiting metastasis formation in vivo 
(Feldmann et al. 2008). IPI-269609 could therefore be subjected to future 
clinical testing for use in humans. A second generation of cyclopamine analogue 
is represented by Saridegib (IPI-926), characterized by improved pharmaceutical 
properties and a favorable pharmacokinetic with respect to cyclopamine and IPI-
269609. IPI-926 has progressed into human clinical trials, in particular, it is in 
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clinical trials phase 1b/2 for metastatic pancreatic cancer (in combination with 
Gemcitabine chemotherapy) and in phase 1 (in combination with monoclonal 
antibody Cetuximab) for recurrent head and neck cancer. IPI-926 is also 
involved in advanced phase 2clinical trials, in particular for ly (MF) and for 
conventional chondrosarcoma (www.clinicaltrials.gov).  
The Shh inhibitor Vismodegib (GDC-0449 Curis-Genetech) has been 
identified through a high-throughput screening of a library of small-molecule 
compounds. GDC-0449 is a potent, selective and orally bioavailable Hedgehog 
antagonist characterized by favorable pharmaceutical properties (Rudin et al. 
2009). Although it is structurally unrelated to cyclopamine and cyclopamine 
analogues, GDC-0449 is able to bind to Smo with high specificity and affinity 
leading to an effective Shh signaling pathway down-regulation (Robarge et al. 
2009). Vismodegib has been approved by the U.S. Food and Drug 
Administration (FDA) for the treatment of either metastatic or locally advanced 
basal cell carcinoma in patients unsuitable for surgical or radiation therapy 
(Rudin 2012). GDC-0449 has entered in phase II trial for metastatic colorectal 
cancer, ovarian cancer, adult brain tumors and childhood medulloblastoma 
(www.clinicaltrials.gov). Nonetheless, acquired resistance to GDC-0449 has 
been observed in patients with medulloblastomas. The D473H mutation has been 
in fact identified in the Smo protein upon Vismodegib treatment (Yauch et al. 
2009). Such mutation results in an amino acid substitution from an aspartic acid 
to a histidine at the position 473 at the boundary between the 6th trans-
membrane domain and the extracellular domain of Smo protein 
(www.mycancergenome.org). Acquired resistance events due to additional Smo 
mutations and variants have been found also in BCC patients treated with 
Vismodegib and in a phase I clinical trials BCC patients treated with Saridegib 
(IPI-926) (Jimeno et al. 2013). Another synthetic, effective, small-molecule Smo 
antagonist is the BMS-833923 (Bristol Myers Squibb). It has entered in phase II 
trial, in combination with Dasatinib (BMS-354825) for chronic myeloid 
leukemia and in phase I trial for BCC, Basal cell nevoid Syndrome, small cell 
lung carcinoma and stomach neoplasm (www.clinicaltrials.gov). HhAntag is 
another small-molecule Smo-binding Shh pathway inhibitor. In 
medulloblastoma in vivo models HhAntag’s ability to block tumor cell 
proliferation and stimulate apoptosis has been demonstrated. It is also able to 
inhibit growth of some Shh-dependent paracrine tumors, although off-target 
effects have been observed at high concentrations (Romer et al. 2004). It has 
recently been shown in vitro that HhAntag is able to block the process of 
chondrogenesis, a characteristic of the pediatric disorder Hereditary Multiple 
Exostoses, by blocking the Shh pathway which is one of its major regulators 
(Mundy et al. 2015). Cur-61414 is a topical synthetic Smo inhibitor. In BCC ex-
vivo mouse model this inhibitor has proven ability to reduce cell proliferation 
and induce apoptotic death (Scales and de Sauvage 2009). It has entered phase I 
clinical trials for sporadic BCC, but the trial was interrupted due to failure 
possibly related of the molecular formulation which did not properly penetrate 
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human skin. Recently a new class of Smo inhibitor has been identified; SMANT 
(Smo Mutant ANTagonist), that exhibit an equivalent activity in inhibiting wild-
type Smo and oncogenic mutated form of Smo (SmoM2 Trp535Leu). This 
creates the possibility to develop new therapeutic strategies for the treatment of 
Smo inhibitor-resistant tumors characterized by Smo gain-of-function mutations. 
In fact, acquired resistance to Smo antagonist represents one of the most 
important obstacles in the treatment of Shh signaling pathway dependent cancer. 
According to recent evidences, cancer cells can acquire resistance to Smo 
inhibitors also through Smo-independent hyper-activation or mutation in another 
Shh signaling downstream component (Infante et al. 2015). Preclinical and 
clinical trials have shown that Smo resistance can be caused for instance by Gli 
protein amplification, up-regulation of non-canonical Gli signaling activation or 
increase of the expression of ATP-binding cassette transporter (ABCs) that 
increase cellular clearance of the drug (Yauch et al. 2009; Rudin et al. 2009). 
 
 
Figure 4. Hedgehog pathway molecular targets. Schematic representation of the 
targets of several Shh inhibitors. 
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1.5.2 Upstream Smoothened inhibitors 
 
  Shh pathway inhibitors may also prevent the ligand binding to its 
receptor Ptch. Hh-blocking antibody 5E1 is a monoclonal antibody used in the 
study of Shh signaling pathway involvement in both embryonic development 
and tumorigenesis. 
It is able to block Shh signaling by inhibiting the binding of all three 
mammalian Hh ligands (Sonic, Indian and Desert Hedgehog ) to Ptch receptor 
(Maun et al. 2010). 5E1 antibody has been employed in in vivo pancreatic 
cancer models proving a decreased tumor volume and a significant reduction of 
desmoplasia (Bailey et al. 2008). Antibodies against Ptch1 receptor were also 
generated with the aim to inhibit the Shh pathway. Anti-patched1 antibody acts 
against an oligo-peptide within the amino acid sequence of the receptor involved 
in ligand binding. A suppressive effect on Shh signaling has been shown in in 
vitro models of pancreatic cancer resulting in a reduction of cell proliferation 
(Nakamura et al. 2007).  
 
1.5.3 Downstream Smoothened inhibitors  
 
  For tumors characterized by mutations downstream of the Smo receptor, 
such as inactivating mutation of SuFu or Gli1 amplification, treatment with Smo 
agonists or with upstream Smo inhibitors is ineffective. In order to block 
downstream Shh signaling, small molecules that are able to inhibit the zinc-
finger transcription factors Gli have been identified. Gli antagonists can be 
classified according to their mechanisms of action in: direct Gli antagonists, that 
are able to block Gli mediated gene transcription, interacting directly with the 
zinc finger proteins; indirect Gli antagonists, that act controlling Gli activation 
mechanisms such as proteolytic degradation and post-translational modifications 
(Infante et al. 2015). GANT61 (Gli-ANTagonist) and GANT58 are two direct 
Gli antagonists, structurally different, but both capable of interfering with Gli1 
and Gli2-mediated transcription (Lauth et al 2007). Both Gli inhibitors act at the 
nuclear level to block Gli induced transcription, in particular GANT61 is able to 
destabilize DNA-Gli complex binding to the 5-zinc finger Gli protein, between 
zinc finger 2 and 3, at the amino acid sites E119 and E167. The GANT61 
specific binding sequence is conserved between Gli1 and Gli2 zinc finger 
proteins, therefore the drug is able to bind both Gli zinc finger proteins 
(Agyeman et al. 2014). 
Gli zinc finger proteins can be activated by oncogenic pathways that bypass 
the Shh signaling pathway. For instance KRAS and BRAF genes, which are 
highly recurrent in colon cancers, activate a ligand-independent pathway, by 
interfering with the PKA-negative regulation and increasing the Gli1 and Gli2 
nuclear localization and transcriptional activation, consequently promoting 
cellular proliferation and tumor progression (Mazumdar et al. 2011; Rovida and 
Stecca 2015). According to recent evidences, GANT61 inhibitor is able to 
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inhibit Gli1 and Gli2 mediated transcription even in tumors where the zinc 
finger proteins activation is mediated by Shh-independent pathways (Lauth et al. 
2007). GANTs inhibitors’ effects on Shh pathway has been demonstrated in in 
vitro models, where both GANT58 and GANT61 lead to inhibition of the tumor 
cell proliferation and tumor cell growth, and in in vivo human prostate cancer 
xenograft models where they suppress tumor growth (Lauth et al. 2007). The 
HDAC (Histone Deacetylases) inhibitors (HDACis) represent another class of 
Shh antagonists that act as indirect Gli antagonists preventing Gli1 and Gli2 
transcriptional activity. Gli1 and Gli2 are acetylated proteins that need a HDAC-
mediated deacetylation for the transcriptional activation. By inhibiting 
deacetylation process of the zinc finger proteins, HDACis prevent the gene 
transcriptional activation and induce Gli1 and Gli2 hyper-acetylation (Coni et al. 
2013). Vorinostat (SAHA), Romidepsin and Belinostat are three HDACis that 
have been approved by the FDA for the treatment of peripheral T cell lymphoma 
(Mottamal et al. 2015). Vorinostat is also in the phase 1 trial (in combination 
with radiation therapies) for treatment of patients with brain metastasis and (in 
combination with hydroxychloroquine, HCQ) for treatment of malignant solid 
tumors. Romidepsin is in the phase 1 trial for solid tumors, multiple myeloma, 
Her2-negative breast cancers and triple negative cancers treatment. Moreover, 
Belinostat is in phase 1 trial for ovarian cancer (plus Carboplatin and/or 
Paclitaxel) and solid tumors and in the phase II for the glioblastoma multiforme 
(GBM) (www.clinicaltrials.gov). 
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1.6 Role of Sonic Hedgehog in thyroid  
 
1.6.1 Sonic Hedgehog in thyroid development 
 
 The sonic hedgehog pathway is involved in the regulation of different 
developmental processes in vertebrates such as left-right axis determination of 
the embryo, tissue patterning and organogenesis (McMahon et al. 2003). 
Moreover Sonic hedgehog has been found to have an important role in proper 
thyroid development. Shh signaling regulates the thyroid symmetric bilobation 
in late organogenesis and represses the improper thyroid differentiation in 
nonthyroid embryonic tissues (Fagman et al.2004). Studies in Shh -/- mice 
models have shown the importance of Sonic Hedgheog pathway in thyroid 
embryonic development. Shh-deficient mice display a correct development of 
thyroid during the early phases of embryogenesis, but, in the late phase, the 
thyroid gland fails the separation into two distinct lobes and appears as a single 
tissue mass displaced unilaterally on the left side of the midline (Fagman et al. 
2004).  Despite the important thyroid dysgenesis, the thyrocytes development 
takes place normally forming polarized epithelium and follicles, although an 
ectopic thyrocytes development outside the thyroid tissue, in particular in the 
primitive respiratory epithelium, has been observed in Shh-/- mice. Thyroid 
hemiagenesis has been described in several genetic syndromes, such as in 
Williams syndrome, a complex genetic disorder characterized by 
developmental delays, cardiovascular disease and learning disabilities caused 
by deletion at 7q11.23 chromosome (Nickerson et al. 1995). Genes interacting 
with Shh signaling, such as Frizzled (G protein-coupled receptor involved in 
the Wnt signaling pathway), have been linked to thys syndrome because 
mapped in the deleted region 7q11.23 (Wang et al.1997), supporting the 
connection between thyroid development and Shh pathway activity.  
 
1.6.2 Sonic Hedgehog in thyroid tumors 
 
 The role of Sonic Hedgehog pathway has been studied and characterized 
also in thyroid tumors. Recent studies have shown a wide expression of Shh 
pathway components such as Ptch and Smo receptors and the transcription factor 
Gli1 in PTC, ATC and in benign follicular thyroid adenoma (FTA) suggesting 
that the Shh pathway activation occurs at an early phase of thyroid tumor 
development. The expression of Shh pathway components has been also found 
in ATC suggesting that an aberrant activation of this pathway can be involved in 
anaplastic thyroid transformation (Hinterseher et al. 2013). Finally, an increased 
expression of the Shh signaling component in medullary thyroid cancer with 
respect to normal thyroid tissue has been demonstrated (Bohinc et al. 2013). 
Nonetheless, the activation of the Shh pathway does not seem to be causative of 
thyroid neoplastic transformation, but it rather seems to promote thyroid 
tumorigenesis and progression in collaboration with other oncogenic pathways 
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(Xu. et al 2012). As previously mentioned, a cross-talk between the MAPK 
pathway and the Shh signaling has been demonstrated in pancreatic 
tumorigenesis. By suppressing the Gli protein degradation process, the 
oncogenic KRAS G12V (Gly12Asp), through the RAF/MEK/ERK pathway, leads 
to increased amount of Gli1 and increases its transcriptional activity. This 
ligand-independent activation has been correlated to progression of pancreatic 
ductal adenoma to carcinoma (Ji et al 2007). Thyroid neoplasms are frequently 
charaterized by genetic alterations that lead to the activation of the MAPK 
signaling pathway however, it has not been described yet a connection between 
MAPK pathway and Shh signaling activation in thyroid neoplastic 
transformation. The nuclear factor kappa-light-chain-enhancer of activated B 
cells (NF-kB) is a transcription factor involved in numerous processes such as 
proliferation, apoptosis and inflammation in both development and 
tumorigenesis (Karin et al 2002). NF-kB involvement in thyroid cancer has also 
been demonstrated (Pacifico and Leonardi 2010). Several NF-kB binding sites 
have been identified at the position +139 of the human Shh promoter region 
(Kasperczyk et al. 2009), therefore NF-kB pathway activation could contribute 
to increased Shh ligand expression levels that can lead to Shh pathway activation 
(in autocrine or paracrine manner) in thyroid cancers. The involvement of p63 
protein in the Shh expression regulation has also been demonstrated. p63 is an 
homologue of the tumor suppressor protein p53 involved in development and 
tumorigenesis. The p63 gene encodes for six different isoforms, TAp63 (α,β,γ) 
and ΔNp63 (α,β,γ), with or without transactivation domain respectively. It has 
been demonstrated that TAp63γ isoform is able to bind the region within the Shh 
promoter, located between nucleotides -228 and -102, inducing Shh 
transactivation (Caserta et al. 2006). P63 seems to be expressed in PTC but not 
in normal thyroid tissue (Unger et al. 2003). Therefore, p63 protein could also be 
implicated in the regulation of the Shh signaling pathway in thyroid 
tumorigenesis.  
Finally, recent evidences suggest the Shh pathway involvement in the 
promotion of thyroid CSC self-renewal in anaplastic cell lines. It is known that 
Gli1 transcription factor activation induces the expression of the zinc finger 
protein Snail (Heiden et al. 2014). Snail is a transcription factor implicated in the 
differentiation of epithelial cells into mesenchymal cells (epithelial - 
mesenchymal transition, EMT) during embryonic development (Cano et al. 
2000). Normal thyroid epithelial cells do not express the Snail transcription 
factor that instead it is widely expressed in thyroid tumor cell lines and tissues 
(Hardy et al. 2007). Recent studies have demonstrated that the Shh pathway 
inhibition, in anaplastic thyroid cancer cells, leads to decreased Snail expression, 
decreased in vitro thyrosphere formation and decreased aldehyde dehydrogenase 
(ALDH) positive CSCs (Heiden et al. 2014).  
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2.0 AIM OF THE STUDY 
 
Sonic Hedgehog pathway has been increasingly studied due to its 
involvement in different human cancers. Several reports suggest the aberrant 
activation of Shh signaling as an important event during neoplastic 
transformation. A number of proliferative and oncogenic pathways have 
been described to cross-interact with Shh pathway in cancer (Pandolfi and 
Stecca 2015). Moreover, Shh signaling has been demonstrated to be one of 
the main signaling pathways activated in tumor stroma and involved in 
tumor-stroma interaction. 
Recent evidences suggest a role of Shh signal transduction in thyroid 
development and tumorigenesis, but the mechanisms of this activation have 
not been described yet. Here we have studied the role of Shh pathway in 
thyroid cancer and its involvement in tumor interaction with 
microenvironment. To this aim we have: 
 
1) Analyzed the expression and activation of Shh signaling components in 
thyroid tumors and tumor-derived cell lines; 
 
2) Studied the molecular mechanisms regulating Shh pathway in thyroid 
cancer; 
 
3) Investigated the Shh signaling involvement in regulating tumor stroma 
interaction in aggressive thyroid cancer (ATC).  
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3.0 MATERIALS AND METHODS 
 
3.1 Compounds 
 
For in vitro experiments, cyclopamine hydrate was purchased by Sigma-
Aldrich (St. Louis, MO, USA). Cyclopamine was dissolved in dimethyl 
sulfoxide (DMSO) at concentration of 3mM and stored at -80°C. Vandetanib 
(ZD6474) and Vemurafenib (PLX4032) were dissolved in DMSO at a 
concentration of 50 mM and stored at -80°C. Azacytidine (Sigma Aldrich) was 
used at a concentration of 4 µM for 48 hours. 
 
3.2 Cell lines 
 
TPC1 cells were originally obtained by M. Nagao (Carcinogenesis 
Division, National Cancer Center Research Institute, Tokyo, Japan). SW1736 
were obtained by N.E. Heldin (University Hospital, S-751 85 Uppsala, Swden). 
BCPAP were obtained by the primary source (N. Fabien, CNRS URA 1454, 
University of Medecine Lyon-Sud, Oullins, France). 8505C, CAL62 anaplastic 
carcinoma cells were purchased from DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) (Salerno et 
al. 2010). OCUT cells were provided by N. Onoda (Osaka University of 
Medicine, Osaka, Japan) in 2005. NTHY are normal human thyrocytes 
immortalized by the Large T of SV40 and were obtained from the European 
Tissue Culture collection. HEK293 cells were from American Type Culture 
Collection (ATCC). All cells grown in either Dulbecco’s Modified Eagle 
Medium (DMEM) or RPMI 1640 medium supplemented with 10% fetal bovine 
serum. All media were supplemented with 2 mM L- glutamine and 100 units/ml 
penicillin-streptomycin (GIBCO). The Fischer rat-derived differentiated thyroid 
follicular cell line PC Cl 3 was grown in Coon’s modified Ham F12 medium 
supplemented with 5% calf serum and a mixture of six hormones (6H): 
thyrotropin (10mU/ml), hydrocortisone (10nM), insulin (10µg/ml), apo-
transferrin (5µg/ml), somatostatin (10ng/ml), and glycyl-histidyl-lysine 
(10ng/ml) (Sigma-Aldrich). PC adoptively expressing several oncogenes have 
been cultured in the same medium as PC but without the 6H. 
 
3.3 Tissue samples 
 
A small set of PTC, ATC and normal thyroid tissue samples snap-frozen 
in liquid nitrogen and maintained at -80°C has been made available by Prof. F. 
Basolo (University of Pisa, Italy). For all of them, formalin-fixed paraffin-
embedded tissue slides were reviewed by 2 pathologists (F. Basolo, C. Ugolini) 
to ensure diagnosis. Informed consent was obtained from the patients and the 
study was approved by the institutional review board committee. Tumor size, 
extra-thyroid invasion, node metastasis, associated thyroid lesions and metastatic 
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deposits were recorded. After surgical resection, tissues were fixed in 10% 
neutral buffered formalin and embedded in paraffin blocks. Sections (4 microns 
thick) were stained with hematoxylin and eosin for histological examination. 
 
3.4 Immunohistochemistry 
 
Formalin-fixed and paraffin-embedded 4- to 5-microns-thick tumor 
sections were deparaffinized, placed in a solution of absolute methanol and 0.3% 
hydrogen peroxide fore 30 min and treated with blocking serum for 20 min. The 
slides were incubated overnight with anti-Gli1 monoclonal antibody (Vectostain 
ABC kits, Vector Laboratories, Inc., Burlingame, CA, USA). As a negative 
control, tissue slides were incubated with isotype-matched IgG1 control 
antibodies. The percentage of positive cells for Gli1 staining was evaluated. 
 
3.5 Immunoblotting 
 
Protein lysates were prepared according to standard procedures. Briefly, 
cells were harvested in lysis buffer (50 mM Hepes, pH 7.5, 150 mM NaCl, 10% 
glycerol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, 10 mM NaF, 10 mM 
sodium pyrophosphate, 1 mM Na3VO4, 10 µg of aprotinin/ml, 10 µg of 
leupeptin/ml) and clarified by centrifugation at 10,000 xg. Nuclear proteins 
extraction was performed using NE-PER® Nuclear and Cytoplasmic Extraction 
Reagents kit (#78835) (Thermo scientific Rockford, USA) according to 
manufacturer’s instructions. Protein concentration was estimated with a 
modified Bradford assay (Bio-Rad) and lysates were subjected to SDS PAGE. 
Membranes were probed with the indicated antibodies. Immune complexes were 
revealed by an enhanced chemiluminescence detection kit (ECL, Amersham 
Pharmacia Biotech). Signal intensity was quantified with the Phosphorimager 
(Typhoon 8600, Amersham Pharmacia Biotech) interfaced with the ImageQuant 
software.  
3.6 Antibodies 
 
Anti Shh (#2207), Anti Gli1 (#2553) and Anti Sufu (#2520) are rabbit 
monoclonal antibodies and were from Cell Signaling Technology. Anti Smo (E-
5) sc-166685 (#C1315), mouse monoclonal antibody and Anti Gli2 (H-300) sc-
28674 (#K2013), rabbit polyclonal antibody, were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Polyclonal antibody anti-Parp (#9542) 
was from Cell Signaling Technology. Monoclonal anti-tubulin (#T9026) was 
from Sigma-Aldrich (St Louis, MO, USA). Secondary antibodies coupled to 
horseradish peroxidase were from Amersham Pharmacia Biotech (Piscataway, 
NJ, USA).  
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3.7 Quantitative real-time PCR 
 
Total RNA was isolated with the RNeasy Kit (Qiagen, Crawley, West 
Sussex, UK). One µg of RNA from each sample was reverse-transcribed with 
the QuantiTect® Reverse Transcription (Qiagen). PCR reactions were 
performed in triplicate and fold changes were calculated with the formula: 2-
(sample 1 ΔCt - sample 2 ΔCt), where ΔCt is the difference between the 
amplification fluorescent thresholds of the mRNA of interest and the mRNA of 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) used as an 
internal reference. 
 
3.8 DNA constructs and Reporter assay 
 
pGL3-Gli-Luc was obtained by PCR-cloning eight copies of the Gli 
binding element into the pGL3 enhancer vector purchased from Promega. 
Luciferase activities present in cellular lysates were assayed using the Dual-
Luciferase Reporter System (Promega, Madison WI, USA). In all cases, total 
amount of transfected plasmid DNA was normalized by adding Renilla 
luciferase reporter gene. Light emission was quantitated using a Monolight 2010 
luminometer (Analytical Luminescence Laboratory). PSec-Shh construct has 
been previously described (Castellone et al. 2015). Data were represented as 
luciferase activity present in each sample and the values plotted were the average 
± SEM of triplicate samples for typical experiments, which were repeated at 
least 3-5 times with nearly identical results. 
 
3.9 Cell transfection and generation of stable cells 
 
Gli1-specific shRNA expression vector (#TG312756) and a scrambled 
control vector (#TR30013) were purchased from OriGene Technologies, 
(Inc.9620 Medical Center Drive, Suite 200 Rockville). Experimental procedures 
were done as follows: the day before transfection, cells were plated in 35-mm 
dishes at 40% of confluence in DMEM supplemented with 10% FBS without 
antibiotics. Two µg of sh-Gli1 and control vector were transfected using 
FuGENE HD Transfection (Promega) reagent according to manufacturer’s 
instructions. Seventy-two hours after transfection, cell medium was 
supplemented with puromycin (Sigma-Aldrich) at final concentration of 1µg/µl 
for 14 days. Stably transfected cells were screened by RT-PCR as previously 
described.  
3.10 Cell proliferation assay 
3x10
4 cells were plated in 60-mm dishes. Cells were kept in RPMI 1640 
or DMEM supplemented with 10% fetal calf serum. The day after plating, 
compounds or vehicle were added. Cells were counted in triplicate every 24 
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hours. To estimate IC50 value, cells were counted after 72 hours. 
3.11 Wound healing assay 
 
A wound was induced on the confluent monolayer cells by scraping a 
gap using a micropipette tip. Photographs were taken at 10X magnification using 
phase-contrast microscopy immediately after wound incision and up to 24 hours 
later. 
 
3.12 Matrigel assay 
 
In vitro invasiveness through Matrigel was assayed using transwell cell 
culture chambers. Briefly, confluent cell monolayers were harvested with 
trypsin/EDTA and centrifuged at 800Xg for 10 minutes. The cell suspension 
(2X105 cells/well) was added to the upper chamber of transwells on pre-hydrated 
polycarbonate membrane filter of 8 µM pore size (Costar) coated with 35µg 
Matrigel (Collaborative Research Inc.). Stromal cells (5X105 cells/well) were 
plated on the bottom of wells. The lower chamber was filled with complete 
medium. Cell dishes were incubated at 37°C in 5% CO2 and 95% air for 48 
hours. Non-migrating cells on the upper side of the filter were wiped off and 
migrating cells on the reverse side of the filter were stained with 0.1% crystal 
violet in 20% methanol for 15 minutes, counted and photographed. 
 
3.13 Spheroid-forming assay 
50 cells per well were plated on ultra-low-attachment 96-well (Corning 
Incorporated, Painted Post, NY, USA) in low serum DMEM medium. Cells were 
maintained in a humidified atmosphere with 5% CO2 at 37°C. Spheroids were 
photographed after 7 and 14 days.  
 
3.14 Statistical analysis 
 
Cell growth comparisons were done applying the Unpaired Student’s t 
test (Instat software, Graphpad Software Inc). All P values were two- sided, and 
differences were considered statistically significant at P <0.01. IC50 values were 
calculated through a curve fitting analysis from last day values using PRISM 
software (Graphpad). P values were statistically significant at P <0.01.  
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4.0 RESULTS 
 
4.1 Sonic Hedgehog pathway expression in thyroid cancer cells  
 
 Recent evidences suggest a role of the Shh pathway in thyroid 
tumorigenesis (Hinterseher et al. 2013; Bohinc et al. 2013). In order to 
characterize the expression levels of Shh pathway molecules in a panel of 
papillary (TPC1, BCPAP) and anaplastic (SW1736, 8505C, CAL62, OCUT) 
thyroid cancer cells compared to immortalized NTHY cell line (derived from non-
tumoral tissues), we performed immunoblotting experiments.  
 
 
 
Figure 5. Shh pathway components are expressed in thyroid cell lines. Total cell lysates 
(50µg) were analyzed with anti-Smo, anti-Gli1, anti-Gli2 and anti-Sufu antibodies. Total tubulin 
level was used for normalization. 
As shown in figure 5, the Smo receptor was expressed in all thyroid cell 
lines and it was slightly increased in TPC1, 8505C and SW1736 cancer cells. 
The Gli1 transcript can undergo alternative splicing producing a truncated Gli1 
variant (tGli1 ~155kDa) lacking the exon 3 and part of exon 4 (41aa deletion), 
and therefore lacking the Sufu binding domain. N’ΔGli1 isoform (~130kDa) 
may also be generated as a result of a post-translational N-terminal truncation of 
Gli1 full length (FL) lacking inhibitory Sufu binding domain and degron domain 
(Carpenter and Lo 2012). Both these variants have been described to be 
particularly expressed and active in cancer (Cao et al. 2012; Amable et al. 2014). 
Interestingly, when analyzing the Gli1 expression levels we found differences in 
the levels of the different isoforms; in particular: Gli1 FL isoform (160kDa) 
seems to be highly expressed in NTHY cell line and modestly expressed in 
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TPC1 cells while all the other cancer cell lines do not express the FL isoform but 
instead they have higher relative levels of the tGli1 isoform compared to NTHY 
cells; N’ΔGli1 isoform levels were higher in TPC1 and SW1736 cells. Gli2 
transcription factor was expressed in all thyroid cell lines, showing lower levels 
in TPC1 and CAL62 cells. Finally, Sufu inhibitor was expressed in a similar 
manner in all thyroid cells with the exception of CAL62, where it was down-
regulated. As we were not able to find an antibody that would recognize the 
Ptch1 receptor in our cells, we performed quantitative RT-PCR (Q-RT-PCR) to 
measure the Ptch1 receptor expression levels in all thyroid cancer cell lines and 
NTHY cells. Ptch1 was slightly up-regulated in 8505C, SW1736 and OCUT 
cells with respect to NTHY cells (it is known that Ptch1 is a transcriptional 
target of Gli1). Interstingly, Ptch1 expression levels were clearly down-regulated 
in BCPAP cell line (Fig.6).  
 
 
 
Figure 6. Ptch1 expression levels in thyroid cells. Q-RT-PCR of Ptch1in thyroid cells. Error 
bars represent standard deviations of experimental triplicates.  
 
 We also analyzed Shh ligand expression in thyroid cancer cells and 
NTHY. Immunoblotting experiments did not show a detectable expression level 
of such protein, therefore we performed quantitative RT-PCR (Q-RT-PCR) 
demonstrating that Shh was expressed at very low levels (amplification was 
reached above 33 cycles) in all thyroid cell lines and slightly up-regulated 
SW1736 cells with respect to NTHY cells (Fig.7). 
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Figure 7. Shh expression levels in thyroid cells. Q-RT-PCR of Shh in thyroid cells. Error 
bars represent standard deviations of experimental triplicates.  
 
4.2 Activation of Sonic Hedgehog pathway in thyroid cancer cells 
 
In order to test the activation of the Shh pathway in thyroid cells, we 
transfected a reporter Gli-Luc plasmid (characterized by the luciferase cDNA 
under the control of 8 tandem Gli1-responsive elements) in a panel of cancer cell 
lines and control NTHY cells. As shown in figure 8, the Gli-Luc reporter is 
activated in all thyroid cancer cell lines but not in NTHY cells suggesting that 
the GLI transcriptional activation, marker of Shh pathway activity, takes place in 
thyroid cancer cells and not NTHY thyroid cells. 
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Figure 8. Shh pathway is active in thyroid cancer cells. Thyroid cells were transfected with 
Gli-Luc reporter (pGL3-Gli-Luc) and 48 hours after transcription Gli activation was measured 
by Luciferase assay. Error bars represent standard deviations of experimental triplicates.  
  
To test whether the Gli transcriptional activation observed in our cells would 
depend on the Smo receptor, we performed a Gli-Luc assay upon treatment with 
the Smo antagonist cyclopamine (10uM) for 24h. Our results, shown in figure 9, 
demonstrate that in cancer cells and not in NTHY there is activation of Gli-Luc 
that is inhibited by cyclopamine. Moreover, cells were responding to stimulation 
with Shh ligand (produced in HEK293T cells upon transfection of a pSec-Shh 
plasmid).  
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Figure 9. Shh pathway is active in thyroid cancer cells but it is inhibited by cyclopamine. 
Thyroid cells were transfected with Gli-Luc reporter (pGL3-Gli-Luc) and after 48 hours Gli 
transcription factors activation was measured by Luciferase assay. Thyroid cells treated with 
cyclopamine 10µM for 24h showed reduction of Gli transcription factors activation. Shh ligand 
stimulation was inducing reporter activation in cancer cells.  
 
4.3 Up-regulation of Sonic Hedgehog pathway components in thyroid 
tumors 
 
 To study the expression of molecules of the Shh pathway in thyroid tumors, 
we evaluated Gli1 expression levels by immunohistochemistry in a panel of 66 
human tissues including: 10 PTCs, 16 ATCs, 10 MTCs, 14 FTCs, 11 benign 
adenomas and 5 normal thyroids (NT). Normal thyroids were all negative for 
Gli1, while tumors were constantly positive, with a proportion of positive cells 
higher in ATC than in adenoma and FTC (Fig.10 and Table I). Among PTC, 
PTC-TCV positivity was particularly high while in PTC-FV was lower and no 
correlation with tumor size or age of the patients was noted. The percentage of 
Gli1 positive cells was higher in males than females (63% vs 48%) (data not 
shown). 
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Figure 10. Gli1 is up-regulated in thyroid tumors. Representative histological sections from 
normal thyroid, PTC and ATC incubated with a mouse monoclonal anti-Gli1 antibody. ATC 
samples showed intense immunoreactivity for Gli1, PTC samples showed a mild expression of 
Gli1 while normal thyroid tissues were completely negative.  
 
 
HISTOTYPE Number of cases Positive cases % positive cells 
(mean) 
PTC 10 9 45 
ATC 16 16 69 
MTC 10 10 66 
FTC 14  10 46 
Adenoma 11 8 42 
Normal 5 0  
 
 
Table I Thyroid samples of different histotypes were stained for Gli1 expression. The majority 
of tumor samples resulted positive for Gli1 while all normal cases were negative. Average 
positive cells were calculated for each histotype.  
 
To determine whether Gli1 up-regulation also occurred at the RNA level, 
we examined a set of normal, PTC and ATC tissues by quantitative RT-PCR. 
Furthermore, we measured the expression of Shh ligand and PTCH1 receptor 
(Fig.11). All components of the Shh pathway, though with significant variability 
among samples, were expressed in tumors at higher levels compared to normal 
tissues (mean of 5 normal thyroids).  
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Figure 11. Shh signaling components are up-regulated in thyroid tumors. Q-RT-PCR of 
Shh, Ptch1 and Gli1 was performed in eight PTCs and six ATCs tumor samples compared to a 
pool of five normal thyroid tissues. The results are the average of three independent experiments. 
Error bars represent standard deviations of experimental triplicates.  
 
4.4 Cyclopamine treatment reduces proliferation of thyroid cancer cells 
 
As luciferase data suggested that cancer cells were sensitive to 
cyclopamine, we decided to measure cyclopamine-inibitory concentration 50 
(IC50) for proliferative thyroid cancer cell lines and NTHY control cells by 
using increasing doses of the compound (Fig.12). Treatment of cancer cells with 
cyclopamine reduced proliferation with an IC50 ranging between 4.64 and 
11.78µM while 20µM of cyclopamine did not reach IC50 in NTHY cells 
suggesting specificity of the drug for transformed cells. 
 
Figure 12. Thyroid cancer cells are sensitive to cyclopamine. Sensitivity of thyroid cells to 
cyclopamine was assessed by cell count. Thyroid cells were treated with different doses of 
cyclopamine (1-5-10-20µM). After 72 hours cells were counted in triplicate. 
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 To test the effect of cyclopamine on thyroid cancer cells viability and 
proliferation we performed a growth curve by treating the cells for 72h. As shown 
in figure 13, 72h of cyclopamine (10µM) treatment decreased the number of 
cancer cells of about 50% (8505C, OCUT, CAL62) and 70-80% (TPC1, SW1736) 
whereas the same treatment did not have any effect on NTHY cells proliferation. 
 
 
 
 
Figure 13. Cyclopamine impairs thyroid cancer cells proliferation. 3x104 cells were plated 
and treated with cyclopamine 10µM. Cells were counted in triplicate every 24 hours. At 72 hours 
the number of thyroid cancer cells was reduced compared to untreated cells.  
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4.5 Silencing of Gli1 transcription factor in OCUT and CAL62 cells impairs 
cell migration  
 
 To characterize the function of Gli in thyroid cancer cells, we stably 
silenced Gli1 expression in OCUT and CAL62 cells by RNA interference 
(Fig.14). The efficacy of knockdown was proved by quantitative RT-PCR, 
showing that short hairpin RNA transfection (shGli1) reduced protein levels by 
about 70% in both cell lines (Fig.14A). 
 
 
 
Figure 14. Gli1 silencing effect on cancer cells proliferation. A) CAL62 and OCUT cells were 
stably transfected with a short hairpin RNA (shGli1) or scrambled plasmid and mRNA 
expression levels were measured by Q-RT-PCR. Error bars represent standard deviations of 
experimental triplicates. B) CAL62 and OCUT cells stably silenced for Gli1 (shGli1) did not 
show reduction of proliferation compared to control cells transfected with scrambled sequence 
(scr). 
Although we did not observe a clear reduction in cell proliferation, most 
likely for the activation of compensatory proliferative mechanisms in the stably 
silenced cells or for the presence of Gli2, that compensates the Gli1 silencing 
(Fig.14B-C), we discovered an impaired cell migration ability, by performing a 
wound healing assay. More specifically, a scraped wound was introduced on a 
confluent monolayer of OCUT and CAL62 stably transfected with shGli1 or 
with scrambled sequence and the cell migration into the wound was monitored 
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after 24 hours. As shown in Fig. 15, OCUT and CAL62 cells transfected with 
the scrambled sequence efficiently migrated into the wound while cells 
transfected with Gli1 shRNA showed reduced migration ability, suggesting a 
role for Shh signaling in regulating migration abilities of thyroid cancer cells. 
 
 
 
Figure 15. Silencing of Gli1 reduces the migration ability of OCUT and CAL62 cells. 
Cancer cells stably silenced for Gli1 were plated to form a confluent monolayer. A scratch 
wound was inflicted on cellular monolayer and after 24 hours cells were photographed. Silenced 
cells showed a reduction of migration ability. 
 
4.6 Mechanisms of Sonic Hedgehog pathway activation in thyroid cancer 
cells 
 
After demonstrating that the Shh pathway is expressed and active in 
thyroid cancer cells, we wondered what was the mechanism of activation. From 
the expression studies we noticed that in BCPAP cells the level of RNA 
expression of the Ptch1 receptor was particularly low (Fig.6); therefore we 
hypothesized a ligand independent activation in this cell line. To check whether 
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the low expression was due to gene deletion, we performed a gene dosage 
through a Copy Number Variation assay (CNV) for Ptch1in BCPAP cells and in 
control cell lines (Fig.16). Interestingly, when using NTHY cells as diploid 
control cells, we found a substantial gene dosage difference compared to 
BCPAP cells, suggesting a single copy deletion of Ptch1 gene. 
 
 
Figure 16. Ptch1 Copy Number assay. Ptch1 gene expression levels were analyzed by 
performing a Copy Number Variation assay (CNV) in a panel of thyroid cells. BCPAP cells 
showed a half reduced dosage of the Ptch1 gene compared to NTHY cells set as diploid control. 
Error bars represent standard deviations of experimental triplicates. 
 
 Because the RNA expression of Ptch was reduced by more than 
half in BCPAP cells (as shown in Fig.6), we asked whether there would be also 
gene methylation. To this aim, we treated BCPAP cells with the DNA 
methyltransferase inhibitor azacytidine (4 µM for 48 hours) (Fig.17). 
Interestingly, treatment with azacytidine recovered the Ptch1 expression 
suggesting gene methylation in BCPAP cells. All together these findings 
indicate that in BCPAP cells the Shh pathway could be activated in a ligand-
independent way, through loss of Ptch receptor due to genetic deletion (on one 
allele) and gene hyper-methylation (on the other allele). 
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Figure 17. De-methylation treatment of Ptch1 gene in BCPAP cells. BCPAP cells were 
treated with azacytidine (4 µM) for 48 hours. After treatment Ptch1 mRNA expression levels 
were measured by Q-RT-PCR. Error bars represent standard deviations of experimental 
triplicates. 
 
Because most of our cancer cell models express low levels of Shh ligand 
(Fig.7), we hypothesized a ligand independent activation of the pathway in these 
cells. Several evidences of a crosstalk between Shh signaling and other signal 
transduction pathways have been reported in different types of cancer (Rovida 
and Stecca 2015). As we know that our thyroid cancer cells are positive for RET 
or BRAF/RAS mutations, we decided to test whether these oncogenes would 
activate the pathway in our cell model, by performing Gli-Luc assay in 
embryonic kidney HEK293T cells transfected with activated forms of BRAF, 
RAS or RET/PTC1 plasmids (Fig.18A). 
Our data, shown in figure 18A, suggest that all these oncogenes are 
inducing Gli-Luc activation. To confirm our findings, we also performed the 
Gli-Luc assay in a rat-derived differentiated thyroid follicular cell line (PC-Cl3) 
stably expressing PTC1 (RET/PTC1), BRAF (BRAFV600E) and HRAS 
(Gly12Val) oncogenes. As shown in figure 18B, transformed PC cells showed 
an increased activity of Gli-Luc reporter compared to wild type PC-Cl3 cells. 
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Figure 18. Oncogenic RAS/BRAF/MAPK and RET pathways activate Shh signaling. A) 
HEK293T cells were transfected with Gli-Luc reporter (pGL3-Gli-Luc) together with 
RET/PTC1 (PTC1), BRAFV600E (BRAF) and RASV12 (RAS) active forms and luciferase 
activity was measured 48 hours after transfection. Gli1 transfection was used as positive control. 
B) A similar experiment was performed also in rat PC-Cl3 cells stably expressing PTC1, BRAF 
and RAS active forms. Error bars represent standard deviations of experimental triplicates. 
 
To check whether Gli-luc activation would result in increased Gli 
transcription, we performed Q-RT-PCR experiments in the same rat transformed 
cells. As shown in figure 19, PC BRAF cells at high levels and PC PTC1 cells at 
lower levels showed increased expression of Gli1 with respect to parental 
untransfected cells. 
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Figure 19. Gli1 is up-regulated in PC cells stably transfected with PTC and BRAF 
oncogenes. Gli1 mRNA expression levels were evaluated by Q-RT-PCR. PC-BRAF and PC-
PTC1 showed high expression levels of Gli1 compared to PC control cells. Error bars represent 
standard deviations of experimental triplicates. 
To confirm the interaction between Shh and BRAF or RET, we treated 
thyroid cancer cell lines with specific Protein Kinase Inhibitors (PKI) targeting 
these oncogenes (Fig.20). In particular, TPC1 (RET/PTC) positive cells were 
treated with Vandetanib (ZD-6474), a TKI that binds to the ATP-binding pocket 
of the RET kinase (at 500nM for 6 and 24 hours) (Knowles et al. 2006), while 
8505C (BRAFV600E) cells were treated with Vemurafenib (PLX-4032), an 
ATP-competitive inhibitor of BRAF (at 500nM for 6 and 24 hours) (Bollag et al. 
2010). As shown in figure 20, Gli-Luc was strongly reduced in TPC1 and 8505C 
cells treated with ZD-6474 and PLX-4032 respectively, in a time depending 
manner, suggesting interaction between RET and BRAF with Shh pathway. 
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Figure 20. Inhibition of RET and BRAF oncogenic pathways impairs Gli-luc activity. TPC1 
and 8505C cells were transfected with Gli-Luc reporter (pGL3-Gli-Luc). After 24 hours cells 
were treated with ZD-6474 and PLX-4032, respectively, at 500nM for 6 and 24 hours and Shh 
activation was evaluated by Luciferase assay. Inhibition of RET and BRAF pathways impaired 
Gli luc activation. Error bars represent standard deviations of experimental triplicates. 
 
 Similarly, Gli1 RNA expression levels were reduced in TPC1 and 
8505C cells treated with ZD-6474 and PLX-4032 respectively, as shown in 
figure 20. All these findings suggest that oncogenic RET and 
RAS/BRAF/MAPK pathways interact with Shh pathway activation in thyroid 
cancer cells, generating a ligand independent (but partially Smo-dependent), non 
canonical mechanism of activation. 
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Figure 21. Gli1 expression levels are supported by RET and RAS oncogenic pathways. 
TPC1 and 8505C cells were treated with ZD-6474 and PLX-4032, respectively, at 500nM for 24 
hours. After drug treatment, mRNA expression levels were evaluated by Q-RT-PCR. Treated 
cells showed a strong reduction of Gli1 expression levels. Error bars represent standard 
deviations of experimental triplicates. 
 
4.7 Sonic Hedgehog pathway activation in tumor-stroma interaction 
 
Because it has been demonstrated, in different cancer models, that Sonic 
Hedgehog is one of the main signaling pathway activated in stroma and involved 
in cancer-stroma interaction, and because in our cells we did not observe high 
expression of the Shh ligand, although the pathway is active and responsive to 
ligand (Fig.9), we decided to investigate the role of Shh pathway in regulating 
the interaction between thyroid cancer cells, in particular anaplastic cells, and 
tumor fibroblasts. Interestingly, when checking the Shh ligand expression levels 
in IMR90 fibroblasts we discovered an higher production of Shh, compared to 
anaplastic CAL62 and OCUT cells (Fig.22). 
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Figure 22. Shh ligand is highly expressed in IMR90 fibroblasts. Shh mRNA expression levels 
were evaluated by Q-RT-PCR. IMR90 cells showed high expression levels of Shh ligand 
compared to CAL62 and OCUT control cells. Error bars represent standard deviations of 
experimental triplicates. 
In order to study if the Shh produced from fibroblasts could activate Shh 
pathway in cancer cells, we stimulated OCUT and CAL62 cells with the 
conditioned medium derived from IMR90 cells as well as with the conditioned 
medium of three different human primary cultures of thyroid mesenchymal 
stromal cells (MSC) (Hematti 2012; Keating 2012) and measured the expression 
levels of several components of the Shh pathway. As shown in figure 23A, both 
thyroid cancer cell populations, upon stimulation, showed increased protein 
levels of Smo receptor (that most likely in not inhibited by Ptch and therefore 
not internalized for degradation) with respect to unstimulated (control) cells. 
Moreover, stimulated CAL62 showed increased amount of Gli1 nuclear protein 
level (checked by cell fractionation) while in OCUT cells we observed the up-
regulation of nuclear Gli2 transcription factor with respect to control cells 
(Fig.23B). 
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Figure 23. Stromal cells stimulation induces up-regulation of Shh signaling components in 
anaplastic thyroid cancer cells. CAL62 and OCUT cells were stimulated with conditioned 
medium derived from IMR90 and mesenchymal cells for 24 hours. After stimulation total cell 
lysates (50µg) were analyzed with anti-Smo, and total tubulin level was used for normalization. 
Nuclear cell lysates (30µg) were analyzed with anti-Gli1 and anti-Gli2. Total Parp level was 
used for normalization. 
To then test whether the increased Gli levels were paralleled by an 
increased transcriptional activity, we performed a Gli-Luc assay in CAL62 cells 
upon MSCs or IMR90 co-cultures. For this experiment, stromal cells orIMR90 
fibroblasts were plated on culture dishes and Gli-Luc transfected cancer cells 
were plated on cover glasses co-cultured in the same dish and then used for 
luciferase reading. Figure 24 shows that stroma co-culture increases Gli 
transcriptional activity in CAL62 cancer cells.  
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Figure 24. Stromal cells stimulation induces Shh signaling activation in anaplastic thyroid 
cancer cells. 3x104 Cal62 cells were plated on cover glass and transfected with Gli-Luc reporter 
(pGL3-Gli-Luc). After 24 hours cells cover glasses were put in co-culture with mesenchymal 
cells or IMR90 fibroblasts for 24 hours. Shh pathway activation was evaluated by Luciferase 
assay. Stromal stimulation increases Shh signaling activation compared to unstimulated cells. 
Error bars represent standard deviations of experimental triplicates. 
  
All together, these results suggest that the Shh ligand secreted by stromal 
fibroblasts is able to activate in paracrine manner the Shh pathway in thyroid 
cancer cells. 
4.8 Sonic Hedgehog pathway activation from stroma cells supports thyroid 
cancer cells invasion, migration and non-adherent growth 
To study the effect of stromal fibroblast stimulation on the biological 
properties of thyroid cancer cells, we first tested cell proliferation by performing 
growth curve analysis of cancer cells stimulated or not stimulated with 
conditioned medium derived from fibroblasts and did not observe significant 
differences (data not shown). We therefore investigated the ability of stimulated 
cancer cells to invade Matrigel. To this aim, stromal cells (IMR90 and MSCs) 
were plated into the bottom of a transwell dish while OCUT and CAL62 cells 
were seeded into the top chamber of transwells coated with Matrigel. As shown 
in Fig. 25 (upper panels) the presence of stromal cells allowed cancer cells to 
invade the Matrigel. To address the role of the Shh pathway in this stimulation, 
we performed the same experiment in the presence of cyclopamine (10 µM). 
Fig. 25 (lower panels) demonstrates that the inhibition of Smo (with 
cyclopamine) reduced the ability of stromal cells to attract cancer cells to invade 
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the matrigel, indicating the involvement of Shh pathway in cancer-stroma 
interaction.  
 
Figure 25. Shh pathway controls the ability of stromal cells to stimulate Matrigel invasion 
of ATC cells. 2X105 Stromal cells were plated on the bottom of wells while OCUT or CAL62 
cells (2X105) were plated into the upper chamber. The lower chamber was filled with complete 
medium. Cyclopamine (10µM) was added to cancer cells (upper chamber) and to stromal cells 
(bottom of well). After 48 hours cells were fixed, stained and photographed. Cancer cells, in the 
presence of stromal cells, showed increased invasion ability compared to control cells. 
Cyclopamine treatment impaired the effect of stromal cells on cancer cells invasion abilities. 
 
To study also the migration properties of stimulated cancer cells, we 
performed a wound healing assay by measuring the ability of CAL62 and OCUT 
cells to close an artificial wound. Our results, in Fig 26A and B, show that 
cancer cells stimulated with stroma conditioned medium have increased cell 
migration ability with respect to control non stimulated cells, because the cells 
are able to close the wound at earlier time points. Again, cyclopamine treatment 
(10 µM) impaired this effect of stroma on cancer cells.  
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Figure 26. Stromal cells stimulation increases cancer cells migration ability. Cancer cells 
were plated to form a confluent monolayer. A scratch wound was inflicted on cellular 
monolayer. Cancer cells were stimulated with conditioned medium derived from IMR90. Cells 
were photographed after different times. Stimulated cells showed a an increased migration ability 
compared to unstimulated cells. Cyclopamine treatment (10µM) reduced cancer cells migration 
compared to control cells.  
 
Finally, to recreate the 3-dimensional organization of tumor-stroma 
interaction, we cultured CAL62 cells alone or together with stromal cells 
(IMR90 and MSC) under non-adherent and low serum conditions. As shown in 
figure 27, IMR90 and MSCs alone did not assemble into aggregates (data not 
shown) while CAL62 cancer cells were able to grow in suspension and form 
spheroid-like complexes. Interestingly, co-culture of thyroid cancer cells with 
IMR90 or MSC cells showed the formation of larger spheroids while 
cyclopamine treatment (10 µM) had a dramatic effect on reducing the size of 
these cell aggregates (Fig. 27).  
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Figure 27. Stromal cells support cancer cells growth in non adherent conditions. CAL62 
cells (50 cells/well) were 62 on ultra-low-attachment 96-well in low serum medium alone or 
together with MSC or IMR90 cells (20 cells/wells). Spheroids were photographed after 7 and 14 
days. Cancer cells, supported by stromal cells, formed larger spheroids and this ability was 
impaired by cyclopamine treatment (10µM). 
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All together, these data suggest that tumor stromal fibroblasts, through Shh 
pathway activation, support thyroid cancer cells invasion, migration and ability 
to grow in non adherent/low serum conditions.  
To finally test whether the co-culture with cancer cells had some 
influence on the stromal counterpart, we stimulated IMR90 fibroblasts with the 
supernatant derived from OCUT and CAL62 cells and tested the amount of Shh 
production. Interestingly, upon cancer cells stimulation, IMR90 showed an 
increased level of Shh RNA (Fig.28A), suggesting that cancer cells can boost 
the Shh production from stromal cells. The produced ligand could either act in a 
paracrine way on cancer cells as well as it could act in an autocrine way on 
stromal cells themselves, because our data demonstrate that IMR90 cells have a 
functional Shh pathway as they respond to a recombinant Shh (pSecShh) and to 
the stimulation with CAL62 and OCUT supernatant (Fig.28 B, C). 
 
Figure 28. Effect of CAL62 and OCUT cells on IMR90 fibroblasts. A) Q-RT-PCR of Shh 
in IMR90 upon stimulation with conditioned medium derived from CAL62 and OCUT cells. 
Q-RT-PCR measuring the expression of Gli1 in IMR90 stimulated with cancer cells 
conditioned medium (B) or with Shh ligand (C).  
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5.0 DISCUSSION 
 
The Hedgehog pathway is a key regulator of embryonic development, 
tissue maintenance and repair, although recent evidences have highlighted its 
involvement in several forms of cancer (Hahn et al. 1996; Amakye et al.2013).  
Different mechanisms of Shh pathway activation have been proposed in cancer 
(Ingham and McMahon 2001). Ligand independent Shh pathway activation has 
been described in some familial cancers, such as basal cell carcinoma, 
medulloblastoma and rhabdomyosarcoma, as a consequence of genetic 
aberrations, targeting mainly the Ptch inhibitory receptor (Pandolfi and Stecca 
2015). Ligand independent non canonical Shh pathway activation has also been 
reported in other tumor models as a result of a crosstalk between Shh signaling 
and different tumorigenic pathways (Rovida and Stecca 2015). Ligand-
dependent autocrine or paracrine activation, has been involved in tumor 
progression and maintenance of other cancers, including gastrointestinal, lung, 
breast and prostate cancers. The paracrine mechanism can either be due to Shh 
secretion by cancer cells and promotion of Gli transcriptional activity in stromal 
cells (direct paracrine), or to Shh ligand secretion by stroma activating the 
pathway in cancer cells (reverse paracrine mechanism) (Bailey et al. 2009). 
Many evidences suggest in fact that the Sonic Hedgehog is one of the main 
pathways involved in tumor-stroma interaction. This finding is interesting 
because tumor microenvironment and tumor-stroma interaction have recently 
been highlighted as new frontiers in studying the cancer biology as well as in 
discovering novel therapeutic approaches to target tumors.  
In this Dissertation, we have addressed the role of the Sonic Hedgehog 
pathway in thyroid cancer and its involvement in thyroid tumor-stroma 
interaction. Several components of the Shh pathway have been demonstrated by 
others (Dong et al. 2014; Nelson et al. 2010) and by ourselves to be up-regulated 
in thyroid tumors and cell lines (Fig. 5, 10, 11). Here we have shown that in 
thyroid cancer cell lines the Gli transcriptional activity is higher compared to 
control cells and that cyclopamine treatment impairs this activation (Fig. 8, 9). 
To then understand the mechanisms regulating Shh signaling in other cell 
models, we have performed several experiments suggesting the existence of a 
ligand independent activation, due to Ptch loss, in BCPAP cells (Fig. 16, 17) and 
a non canonical activation, through the cross-talk between Shh signaling and 
other oncogenic pathways (such as RAS/BRAF/MAPK and RET pathways) in 
our cells lines, positive for these oncogenes (Fig. 18-21). We have also 
demonstrated that in thyroid cancer cells the Shh pathway can be activated 
through a ligand dependent paracrine mechanism, with Shh ligand produced by 
stromal cells and inducing Gli activation in cancer cells (recerse paracrine). Our 
co-culture experiments and stimulation with conditioned-medium suggest that 
stromal cells (IMR90 and MSCs) support cancer cells invasion, migration and 
non-adherent growth abilities in a Shh dependent manner (as cyclopamine 
impairs these effects) (Fig. 23-27). Interestingly, we also observed an increased 
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Shh production in fibroblasts stimulated with conditioned medium derived from 
cancer cells, suggesting a bi-directional paracrine effect (Fig. 28).  
Our evidences suggest therefore that the Hedgehog pathway can be 
considered as a novel prognostic marker and therapeutic target to be used alone 
or in combinatorial protocols in aggressive thyroid cancers. Combinatorial 
strategies are increasingly expanding in the treatment of several types of cancer 
characterized by non-canonical Shh signaling activation. For instance, a 
combined inhibition therapy of Shh pathway and MEK or AKT, has shown to 
produce synergistic effects in reducing melanoma and cholangiocarcinoma cell 
proliferation in vitro (Stecca et al. 2007; Jinawath et al. 2007). Moreover, Smo 
inhibitors, in combinatorial strategies with EGFR inhibitors, have been described 
in several preclinical models. In pancreatic cancer cells for instance, EGFR 
inhibitor gefinitib in combination with cyclopamine, has shown a tumor growth 
decrease and apoptotic rate increase (Chitkara et al. 2012) while in prostate 
cancer cells, cyclopamine in combination with gefitinib and docetaxel treatment 
has shown an inhibitory effect on proliferation and invasiveness (Mimeault et al. 
2007). Stromal cells are able to support tumorigenesis and, at the same time, 
protect cancer from the effect of chemotherapeutic drugs. Therefore, 
combination treatments targeting both the stroma and the cancer cells with Shh 
inhibitor IPI-926, together with chemotherapy drug gemcitabine, has shown 
depletion of stroma and increased drug delivery in a preclinical mouse model of 
pancreatic cancer proving efficacy of combinatorial strategy against both cancer 
cells and stroma (Olive et al. 2009). At the moment there are no clinical studies 
in thyroid models demonstrating the correlation between stroma inhibition and 
reduced aggressiveness. We are confident that our data can shed new light on the 
possibility to target Shh pathway in thyroid cancer cells as well as in tumor 
microenvironment, suggesting novel therapeutic possibilities to fight aggressive 
anaplastic cancer for which currently there is no effective therapy. 
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6.0 CONCLUSIONS 
 
In conclusion, here we show that Shh pathway is involved in thyroid 
neoplastic transformation supporting cancer cell proliferation, migration and 
invasion abilities. We hypothesize the existence of ligand independent 
mechanisms: in BCPAP cells that do not express the Ptch receptor and do not 
respond to Shh (1) as well as in other cell lines positive for RAS/BRAF or RET 
activating mutations where cross-talk mechanisms with Shh signaling, have been 
decribed to interefere with PKA inhibitory mechanisms and increase Gli amount 
as well as nuclear localization and transcriptional activity, promoting thyroid 
cancer cell growth (2) (Rovida and Stecca, 2015). Moreover, we demonstrate the 
presence of ligand dependent inverse paracrine activation mechanisms, where 
Shh ligand is secreted by stromal cells and acts in a paracrine way on cancer 
cells to support invasion, migration and tumorigenicity (3) (Fig.27). 
 
Figure 29. Schematic representation of Shh pathway activation mechanisms in thyroid 
cancer cells. 
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